T lymphocyte-mediated pyroptosis: A new regulatory mechanism in non-viral liver disease [0.03%]
T淋巴细胞介导的焦亡：非病毒性肝病中的一种新的调节机制
Wanyuan Xiong,Zibing Qian,Xiaorong Mao et al.
Wanyuan Xiong et al.
T lymphocyte-mediated pyroptosis plays an important role in the development of non-viral liver diseases. Pyroptosis as a programmed cell death process, has been a hot topic of research on disease pathogenesis in recent years. As one of the ...
LncRNA ZFAS1 ameliorates injury led by non-alcoholic fatty liver disease via suppressing lipid peroxidation and inflammation [0.03%]
长链非编码RNA ZFAS1通过抑制脂质过氧化和炎症来改善由非酒精性脂肪肝引起的损伤
Lu Liu,Sen Sun,Xiaohua Li
Lu Liu
Background: Nonalcoholic fatty liver disease (NAFLD) is known to aggravate metabolic disturbance and increase the risk of complications. The purpose of the present study was to explore the mechanism underlying the clinica...
Global burden of non-alcoholic fatty liver disease in 204 countries and territories from 1990 to 2019 [0.03%]
1990年至2019年全球204个国家和地区非酒精性脂肪肝疾病负担分析
Hongzhan Tian,Kexin Zhang,Zongguang Hui et al.
Hongzhan Tian et al.
Background: Non-alcoholic fatty liver disease (NAFLD) is a growing epidemic linked to metabolic disease and is the most prevalent cause of chronic liver disease. We, therefore, designed the study to analyze the global and...
Efficacy and safety of no-touch radiofrequency ablation for small hepatocellular carcinoma-a systematic review and single-arm meta-analysis [0.03%]
无接触射频消融治疗小肝细胞癌的疗效和安全性-系统评价及单臂Meta分析
Fei Du,Lingkai Zhang,Yongxuan Zhang et al.
Fei Du et al.
Objective: The purpose of this study was to report the efficacy and safety of no-touch radiofrequency ablation (NT-RFA) in the treatment of small hepatocellular carcinoma (HCC). ...
Alpha-1-Antitrypsin Pi*MZ variant increases risk of developing hepatic events in nonalcoholic fatty liver disease patients [0.03%]
α-1抗胰蛋白酶Pi*MZ变异会增加非酒精性脂肪肝患者的肝病发生风险
Arvind R Murali,Sameer Prakash,Antonio J Sanchez
Arvind R Murali
Aims: Heterozygous alpha-1-antitrypsin (A1AT) Pi*MZ variant has been shown to increase the risk of developing liver cirrhosis in patients with non-alcoholic fatty liver disease (NAFLD). We aimed to determine the associati...
Metabolic-associated fatty liver disease and the risk of cardiovascular disease [0.03%]
与代谢相关的脂肪肝病和心血管疾病的风险
Pengwei Zhang,Xianhui Dong,Wei Zhang et al.
Pengwei Zhang et al.
Background: With the gradual adoption of new metabolic-associated fatty liver disease (MAFLD) definitions in clinical practice, the relationship between MAFLD and cardiovascular disease (CVD) risk remains unclear. Similar...
Improving colorectal cancer screening - consumer-centred technological interventions to enhance engagement and participation amongst diverse cohorts [0.03%]
改善结直肠癌筛查 - 以消费者为中心的技术干预措施，提高不同群体的参与度和参与感
Saleem Ameen,Ming Chao Wong,Paul Turner et al.
Saleem Ameen et al.
The current "Gold Standard" colorectal cancer (CRC) screening approach of faecal occult blood test (FOBT) with follow-up colonoscopy has been shown to significantly improve morbidity and mortality, by enabling the early detection of disease...
Predictive factors of radiofrequency ablation failure in the treatment of dysplastic Barrett's esophagus [0.03%]
射频消融治疗巴雷特食管上皮内瘤变失败的预测因素
Simon Weiss,Anna Pellat,Felix Corre et al.
Simon Weiss et al.
Introduction: Radiofrequency ablation (RFA) has become the recommended endoscopic treatment for flat dysplastic Barrett's esophagus. However, the outcomes of this treatment are variable across European countries. Our aim ...
Comparison of the effects of lenvatinib and sorafenib on survival in patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis [0.03%]
仑伐替尼与索拉非比对晚期肝细胞性肺癌患者生存率影响的对比：系统性综述和荟萃分析
Lingbo Hu,Yu Zheng,Jiangyin Lin et al.
Lingbo Hu et al.
Background and aim: The first-line systemic therapy for advanced hepatocellular carcinoma (HCC) involves the use of sorafenib and lenvatinib. The present meta-analysis attempted to compare the therapeutic safety and effec...
The addition of camrelizumab is effective and safe among unresectable hepatocellular carcinoma patients who progress after drug-eluting bead transarterial chemoembolization plus apatinib therapy [0.03%]
卡瑞利珠单抗的添加对于经药物洗脱 beads 经动脉化疗栓塞联合阿帕替尼治疗后进展的不可切除肝细胞癌患者是有效和安全的
Manzhou Wang,Limin Sun,Xinwei Han et al.
Manzhou Wang et al.
Objective: Camrelizumab synergizes with apatinib or transarterial chemoembolization via tumor immunity and chemosensitivity. This study aimed to investigate the efficacy and safety of camrelizumab plus apatinib with or wi...